Yes what they say is good, but they are talking 2 different subjects: 1. Avacta Precision platform for tumour microenvironment activated chemotherapy and novel Affimer® biotherapeutics platform – to deliver first-in-class cancer therapies that boost efficacy and minimise off target toxicity. 2. Precision medicine :- comes from the idea of treating each patient as a unique individual.
Poor report, one of them talking about avct precision platform and the other spouting about precision technology ( ie personalised therapies) As we know they are two different entities. Laughable.
Not spending, Agree if you are a LTH then believe in the science and hold. It works. For the traders:- Short term there is a gap on the charts at 122, which MAY be filled, then after this dip it's upwards.
Also:- Tomorrow we will publish a video explainer by Avacta CEO Alastair Smith to walk investors through the data presented in the poster as well as providing an AVA6000 clinical data review. The video will be shared here and added to: https://avacta.com/investors/documents-presentations/. #AVCT
Same as you, new to share, but some very good questions. Hope Myles reads this board, he's a man who will know, or one of the other knowledgeable regulars (such as Trek).
Chris, This is a free board and many would welcome your views. Don't let 1 individual put you off for the sake of others. If he doesn't want to read your posts, he can always filter you.
Reads well for all projects and has cash in bank of around £12m ( 4.9m from 2022 plus raise of 7.3m march). Hoping they can engage more partners for faster development.